|
英文药名: Epivir (Lamivudine Tablets)
中文药名: 拉米夫定片和口服液
生产厂家: Glaxo Smith Kline
药品名称
益平维 薄膜衣片 [ Epivir ]
成份: 拉米夫定 Lamivudine
适应症
与其它抗逆转录病毒药物联合使用，用于治疗人类免疫缺陷病毒（HIV）感染的成人和儿童。
用法用量
12岁以上患者 150 mg bid或300 mg qd。3月至12岁儿童 4 mg/kg bid，最大剂量为300 mg/天。
肾损害者减量使用。
任何疑问，请遵医嘱！
FDA妊娠分级
C级： 动物研究证明药物对胎儿有危害性（致畸或胚胎死亡等），或尚无设对照的妊娠妇女研究，或尚未对妊娠妇女及动物进行研究。本类药物只有在权衡对孕妇的益处大于对胎儿的危害之后，方可使用。
注意事项
不要单独使用本药治疗。用药过程中注意监测胰腺炎的发生。使用核苷类似物后有出现乳酸酸中毒的报道，当患者出现原因不明的代谢性/乳酸酸中毒、进行性肝肿大或转氨酶迅速升高，应立即停止治疗。患肝肿大、肝炎或有肝脏疾病危险因素和脂肪肝的患者慎用。患有严重免疫缺陷的HIV感染患者在开始抗逆转录病毒药物治疗时，可引起无症状的或残余机会性感染的炎症反应，并导致严重的临床状况或症状恶化，如巨细胞病毒视网膜炎，分支杆菌感染和卡氏肺囊虫肺炎。妊娠的前3个月不要使用。感染HIV的母亲不应母乳喂养。
不良反应
血象异常，头痛、失眠，极罕见外周神经病或感觉异常，咳嗽、鼻部症状，胃肠道反应、罕见血清淀粉酶升高、胰腺炎，少见肝酶一过性升高、罕见肝炎，皮疹、脱发，关节痛、肌肉功能失调 、罕见横纹肌溶解，疲劳、不适、发热。
药物相互作用
勿与治疗卡氏肺囊虫肺炎及弓形体病时大剂量复方甲唑合用；不推荐与静注的更昔洛韦或膦甲酸盐；扎西他滨合用。
Brand Name: Pascal Lamy
Other name (s): lamivudine, Lamy hepatitis B virus, Lamivudina
Drug Class: Nucleoside Reverse Transcriptase Inhibitors
Lamy is also known as lamivudine or lamivudine, is a type of medicine called a nucleoside reverse transcriptase inhibitors (NRTI's). NRTIs block reverse transcriptase protein of HIV to their own needs, to make more copies.
HIV / AIDS-related purposes
Lamivudine in the United States FDA approved November 17, 1995, in the treatment of HIV infection in adults and children over 3 months old the other combination of antiretroviral drugs. Although this approach did not receive FDA approval, lamivudine can be used to prevent infection with HIV and other health care workers come upon them unexpectedly and the job.Lamivudine alone or with other antiretroviral drug combinations, and exposure to the virus not cure or prevent HIV infection or AIDS, will not reduce the virus to pass the risk to others.
Formulation / Management
Lamivudine appears liquid and tablet form, oral. Lamivudine can also be combined with the NRTI zidovudine (in a tablet called Combivir) and NRTI abacavir sulfate (in a film called Epzicom), and with the NRTIs abacavir sulfate and Qi AZT (in tablet Trizivir). Also equipped with lamivudine of hepatitis B virus (HBV) infection treatment with low doses of liquid and tablet form (called Lamy hepatitis B virus). The form of low doses of lamivudine individuals who have only hepatitis B virus infection. Personal everyone hepatitis B virus and HIV infection should not use this low dose.
The recommended daily dose
The recommended adult daily dose of 300 mg lamivudine once daily or 150 mg twice a day. For children 3 months to 16 years old, the recommended dose of 4 mg / kg, up to 150 mg twice a day. The recommended dose of lamivudine may reduce the renal function.Some individuals may benefit from different patients with different doses of lamivudine. Lamivudine individuals should always follow medical advice.
Taboo
Individuals should be told before taking this medicine, doctor of any medical problems.
Possible side-effects
With its expected effects, lamivudine may cause some adverse effects. The drug's serious side effects, including severe abdominal pain or abdominal pain or fullness, nausea, in the hands tingling, burning, numbness, pain, arms, feet or legs and vomiting. Individuals should tell their doctor if they have side effects, these side effects may not be any serious effects.Other may reduce or disappear with continued use of medicine. The drug less serious side effects include mouth ulcers, discharging ears, or ear swelling, skin redness, pain, ulcers, or in the lips, tongue, white spots, or inside the mouth, neck, armpits, groin swelling and pain or spots; and unusually warm skin. Individuals should tell the doctor if these side effects continue or distress.
Drug and food interactions
Doctors should inform any other drugs being taken, including prescription drugs, non-prescription (over-the-counter) and herbal.
Manufacturer information
Lamy
GlaxoSmithKline
Lamivudine
GlaxoSmithKline | 
